Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fuji
Federal Trade Commission
UBS
Accenture
Argus Health
Cipla
Queensland Health
Fish and Richardson
US Department of Justice
Moodys

Generated: February 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,563,608

« Back to Dashboard

Which drugs does patent 8,563,608 protect, and when does it expire?

Patent 8,563,608 protects VASCEPA and is included in one NDA.

This patent has twenty-four patent family members in fourteen countries.
Summary for Patent: 8,563,608
Title:Methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
Abstract: The present invention relates to methods of reducing triglyceride levels in statin-treated subjects having a triglyceride level of 500 mg/dl to 1500 mg/dl.
Inventor(s): Manku; Mehar (England, GB), Osterloh; Ian (Kent, GB), Wicker; Pierre (Mystic, CT), Braeckman; Rene (Richboro, PA), Soni; Paresh (Mystic, CT)
Assignee: Amarin Pharmaceuticals Ireland Limited (Dublin, IE)
Application Number:13/417,899
Patent Claim Types:
see list of patent claims
Use; Dosage form;

Drugs Protected by US Patent 8,563,608

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Amarin Pharms VASCEPA icosapent ethyl CAPSULE;ORAL 202057-001 Jul 26, 2012 RX Yes Yes ➤ Sign Up ➤ Sign Up METHOD OF REDUCING TG LEVELS IN PATIENT SUFFERING FROM SEVERE HYPERTRIGLYCERIDEMIA ➤ Sign Up
Amarin Pharms VASCEPA icosapent ethyl CAPSULE;ORAL 202057-002 Feb 16, 2017 RX Yes No ➤ Sign Up ➤ Sign Up METHOD OF REDUCING TG LEVELS IN PATIENT SUFFERING FROM SEVERE HYPERTRIGLYCERIDEMIA ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,563,608

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,618,166 Methods of treating mixed dyslipidemia ➤ Sign Up
9,056,088 Pharmaceutical compositions comprising fatty acids ➤ Sign Up
8,680,144 Methods of treating mixed dyslipidemia ➤ Sign Up
8,691,871 Methods of treating mixed dyslipidemia ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,563,608

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2010241567 ➤ Sign Up
Brazil PI1014405 ➤ Sign Up
Canada 2759176 ➤ Sign Up
China 102413825 ➤ Sign Up
China 104042617 ➤ Sign Up
China 106822080 ➤ Sign Up
China 107233337 ➤ Sign Up
Colombia 6470839 ➤ Sign Up
European Patent Office 2424521 ➤ Sign Up
Hong Kong 1202795 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
Harvard Business School
US Department of Justice
Argus Health
Fish and Richardson
Chubb
Fuji
AstraZeneca
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot